| scholarly article | Q13442814 |
| P2093 | author name string | Yan Liu | |
| Wendu Duan | |||
| P2860 | cites work | The evolving landscape of therapeutic drug development for hepatocellular carcinoma | Q45082632 |
| Redox-responsive and pH-sensitive nanoparticles enhanced stability and anticancer ability of erlotinib to treat lung cancer in vivo | Q47135282 | ||
| Hyaluronidase Embedded in Nanocarrier PEG Shell for Enhanced Tumor Penetration and Highly Efficient Antitumor Efficacy. | Q50863246 | ||
| Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma | Q50914838 | ||
| N-Acetylgalactosamine-Targeted Delivery of Dendrimer-Doxorubicin Conjugates Influences Doxorubicin Cytotoxicity and Metabolic Profile in Hepatic Cancer Cells | Q51045603 | ||
| Co-delivery of doxorubicin and pH-sensitive curcumin prodrug by transferrin-targeted nanoparticles for breast cancer treatment | Q51200478 | ||
| A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems | Q52437888 | ||
| Transcription activator, hyaluronic acid and tocopheryl succinate multi-functionalized novel lipid carriers encapsulating etoposide for lymphoma therapy | Q53321197 | ||
| In vivo evaluation of a self-nanoemulsifying drug delivery system for curcumin | Q53531777 | ||
| Stimuli-responsive PEGylated prodrugs for targeted doxorubicin delivery | Q57182932 | ||
| Pegylated liposomal doxorubicin and gemcitabine in patients with advanced hepatocellular carcinoma: results of a phase 2 study | Q82354951 | ||
| Global cancer statistics | Q22241238 | ||
| A concise review of updated guidelines regarding the management of hepatocellular carcinoma around the world: 2010-2016 | Q26752478 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Stimuli-Responsive Materials for Controlled Release of Theranostic Agents. | Q30406730 | ||
| Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma | Q33361810 | ||
| A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. | Q33368982 | ||
| Evaluation of pullulan-functionalized doxorubicin nanoparticles for asialoglycoprotein receptor-mediated uptake in Hep G2 cell line | Q35673292 | ||
| Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy | Q35746919 | ||
| Antitumor activity of sorafenib-incorporated nanoparticles of dextran/poly(dl-lactide-co-glycolide) block copolymer | Q35799514 | ||
| Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy | Q35998388 | ||
| The changing pattern of epidemiology in hepatocellular carcinoma | Q36084797 | ||
| Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling | Q36288956 | ||
| Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Q36610990 | ||
| Super pH-sensitive multifunctional polymeric micelle for tumor pH(e) specific TAT exposure and multidrug resistance | Q37016869 | ||
| Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. | Q37072534 | ||
| N-acetylgalactosamine-functionalized dendrimers as hepatic cancer cell-targeted carriers | Q37087186 | ||
| Saccharide modified pharmaceutical nanocarriers for targeted drug and gene delivery | Q37635250 | ||
| Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial | Q37809940 | ||
| Molecularly targeted therapy for advanced hepatocellular carcinoma in 2012: current status and future perspectives | Q38030783 | ||
| Prodrug-based nanoparticulate drug delivery strategies for cancer therapy | Q38274152 | ||
| Systemic therapy of hepatocellular carcinoma: current and promising | Q38447665 | ||
| Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. | Q38711169 | ||
| pH sensitive polymeric complex of cisplatin with hyaluronic acid exhibits tumor-targeted delivery and improved in vivo antitumor effect | Q38822491 | ||
| Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma | Q39585554 | ||
| A pH/enzyme-responsive tumor-specific delivery system for doxorubicin | Q39703580 | ||
| RGD peptide targeted lipid coated nanoparticles for combinatorial delivery of sorafenib and quercetin against hepatocellular carcinoma | Q40688909 | ||
| Layer-by-layer nanoparticles co-loading gemcitabine and platinum (IV) prodrugs for synergistic combination therapy of lung cancer | Q41382500 | ||
| Irinotecan and 5-fluorouracil-co-loaded, hyaluronic acid-modified layer-by-layer nanoparticles for targeted gastric carcinoma therapy | Q41383019 | ||
| Protective effects on myocardial infarction model: delivery of schisandrin B using matrix metalloproteinase-sensitive peptide-modified, PEGylated lipid nanoparticles | Q42280481 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | nanoparticle | Q61231 |
| hepatocellular carcinoma | Q1148337 | ||
| doxorubicin | Q18936 | ||
| P304 | page(s) | 2149-2161 | |
| P577 | publication date | 2018-07-11 | |
| P1433 | published in | Drug Design, Development and Therapy | Q2566724 |
| P1476 | title | Targeted and synergistic therapy for hepatocellular carcinoma: monosaccharide modified lipid nanoparticles for the co-delivery of doxorubicin and sorafenib. | |
| P478 | volume | 12 |
| Q90728049 | Combination of light-driven co-delivery of chemodrugs and plasmonic-induced heat for cancer therapeutics using hybrid protein nanocapsules |
| Q64238257 | Evaluation of Polymer Nanoformulations in Hepatoma Therapy by Established Rodent Models |
| Q92462117 | In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy |
| Q101557486 | Surface receptor-mediated targeted drug delivery systems for enhanced cancer treatment: A state-of-the-art review |
Search more.